209 related articles for article (PubMed ID: 31686850)
1. Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer.
Wang W; Wang J; Zhang X; Liu G
Onco Targets Ther; 2019; 12():7451-7457. PubMed ID: 31686850
[TBL] [Abstract][Full Text] [Related]
2. CircSETDB1 knockdown inhibits the malignant progression of serous ovarian cancer through miR-129-3p-dependent regulation of MAP3K3.
Li B; Zhang L
J Ovarian Res; 2021 Nov; 14(1):160. PubMed ID: 34789310
[TBL] [Abstract][Full Text] [Related]
3. Hypoxic tumor-derived exosomal circular RNA SETDB1 promotes invasive growth and EMT via the miR-7/Sp1 axis in lung adenocarcinoma.
Xu L; Liao WL; Lu QJ; Zhang P; Zhu J; Jiang GN
Mol Ther Nucleic Acids; 2021 Mar; 23():1078-1092. PubMed ID: 33614250
[TBL] [Abstract][Full Text] [Related]
4. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
[TBL] [Abstract][Full Text] [Related]
5. Early onset neutropenia: a useful predictor of chemosensitivity and favorable prognosis in patients with serous ovarian cancer.
He Y; Li T; Liu J; Ou Q; Zhou J
BMC Cancer; 2020 Feb; 20(1):116. PubMed ID: 32050944
[TBL] [Abstract][Full Text] [Related]
6. MMP-16 as a New Biomarker for Predicting Prognosis and Chemosensitivity of Serous Ovarian Cancer: A Study Based on Bioinformatics Analysis.
Wang W; Liu Y; Yang Y; Huang X; Hou Y
Crit Rev Eukaryot Gene Expr; 2021; 31(4):1-8. PubMed ID: 34587431
[TBL] [Abstract][Full Text] [Related]
7. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
8. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
9. ALOX5AP Predicts Poor Prognosis by Enhancing M2 Macrophages Polarization and Immunosuppression in Serous Ovarian Cancer Microenvironment.
Ye X; An L; Wang X; Zhang C; Huang W; Sun C; Li R; Ma H; Wang H; Gao M
Front Oncol; 2021; 11():675104. PubMed ID: 34094977
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome-based stemness indices analysis reveals platinum-based chemo-theraputic response indicators in advanced-stage serous ovarian cancer.
Sun X; Liu Q; Huang J; Diao G; Liang Z
Bioengineered; 2021 Dec; 12(1):3753-3771. PubMed ID: 34266348
[TBL] [Abstract][Full Text] [Related]
11. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
12. Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer.
Ning L; Lang J; Wu L
BMC Cancer; 2022 Jan; 22(1):6. PubMed ID: 34980005
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer.
Qiu JJ; Lin YY; Ding JX; Feng WW; Jin HY; Hua KQ
Int J Oncol; 2015; 46(6):2497-505. PubMed ID: 25845387
[TBL] [Abstract][Full Text] [Related]
14. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
Abdelrahman AE; Fathy A; Elsebai EA; Nawar N; Etman WM
Ann Diagn Pathol; 2018 Aug; 35():27-37. PubMed ID: 30072015
[TBL] [Abstract][Full Text] [Related]
16. Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer.
Wang Y; Liu P; Xu Y; Zhang W; Tong L; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Feb; 75(2):255-62. PubMed ID: 25428515
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
18. High Expression Levels of AGGF1 and MFAP4 Predict Primary Platinum-Based Chemoresistance and are Associated with Adverse Prognosis in Patients with Serous Ovarian Cancer.
Zhao H; Sun Q; Li L; Zhou J; Zhang C; Hu T; Zhou X; Zhang L; Wang B; Li B; Zhu T; Li H
J Cancer; 2019; 10(2):397-407. PubMed ID: 30719133
[TBL] [Abstract][Full Text] [Related]
19. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
Han C; Bellone S; Siegel ER; Altwerger G; Menderes G; Bonazzoli E; Egawa-Takata T; Pettinella F; Bianchi A; Riccio F; Zammataro L; Yadav G; Marto JA; Penet MF; Levine DA; Drapkin R; Patel A; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2018 Jun; 149(3):585-591. PubMed ID: 29572027
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-to-lymphocyte ratio is associated with sensitivity to platinum-based chemotherapy and prognosis in patients with advanced serous ovarian carcinoma.
Fukuda T; Kawanishi M; Awazu Y; Nanno S; Shimomura M; Inoue Y; Matsubara H; Yamauchi M; Kasai M; Hashiguchi Y; Ichimura T; Yasui T; Sumi T
Mol Clin Oncol; 2021 Oct; 15(4):217. PubMed ID: 34476101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
